Cargando…

Long-Term Treatment of Postmenopausal Osteoporosis

Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. A large gap currently exists in the primary prevention of fractures, and studies show that an estimated 80% to 90% of adults do not receive appropriate osteoporosis management even in the secondary prevent...

Descripción completa

Detalles Bibliográficos
Autor principal: Brown, Jacques P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258325/
https://www.ncbi.nlm.nih.gov/pubmed/34154042
http://dx.doi.org/10.3803/EnM.2021.301
_version_ 1783718481050468352
author Brown, Jacques P.
author_facet Brown, Jacques P.
author_sort Brown, Jacques P.
collection PubMed
description Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. A large gap currently exists in the primary prevention of fractures, and studies show that an estimated 80% to 90% of adults do not receive appropriate osteoporosis management even in the secondary prevention setting. Case finding strategies have been developed and effective pharmacological interventions are available. This publication addresses how best to use the pharmacological options available for postmenopausal osteoporosis to provide lifelong fracture protection in patients at high and very high risk of fracture. The benefit of osteoporosis therapies far outweighs the rare risks.
format Online
Article
Text
id pubmed-8258325
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Korean Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-82583252021-07-19 Long-Term Treatment of Postmenopausal Osteoporosis Brown, Jacques P. Endocrinol Metab (Seoul) Review Article Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. A large gap currently exists in the primary prevention of fractures, and studies show that an estimated 80% to 90% of adults do not receive appropriate osteoporosis management even in the secondary prevention setting. Case finding strategies have been developed and effective pharmacological interventions are available. This publication addresses how best to use the pharmacological options available for postmenopausal osteoporosis to provide lifelong fracture protection in patients at high and very high risk of fracture. The benefit of osteoporosis therapies far outweighs the rare risks. Korean Endocrine Society 2021-06 2021-06-22 /pmc/articles/PMC8258325/ /pubmed/34154042 http://dx.doi.org/10.3803/EnM.2021.301 Text en Copyright © 2021 Korean Endocrine Society https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Brown, Jacques P.
Long-Term Treatment of Postmenopausal Osteoporosis
title Long-Term Treatment of Postmenopausal Osteoporosis
title_full Long-Term Treatment of Postmenopausal Osteoporosis
title_fullStr Long-Term Treatment of Postmenopausal Osteoporosis
title_full_unstemmed Long-Term Treatment of Postmenopausal Osteoporosis
title_short Long-Term Treatment of Postmenopausal Osteoporosis
title_sort long-term treatment of postmenopausal osteoporosis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258325/
https://www.ncbi.nlm.nih.gov/pubmed/34154042
http://dx.doi.org/10.3803/EnM.2021.301
work_keys_str_mv AT brownjacquesp longtermtreatmentofpostmenopausalosteoporosis